Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.

Inclusion criteria: * Patients who have started at first time on Jardiance® in accordance with the approved label in Korea for heart failure (HF) * Chronic heart failure (New York Heart Association (NYHA) class II-IV) * Age ≥ 19 years at enrolment * Patients who have signed on the data release consent form Exclusion criteria: * Patients with previous exposure to Jardiance® * Known allergy or hypersensitivity to active ingredients empagliflozin or to any of the excipients * Patients with type 1 diabetes or with prior history of diabetic ketoacidosis (DKA) * Patient with renal impairment with estimated Glomerular Filtration Rate (eGFR) \< 20 mL/min/1.73 m² * Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption * Patient who are pregnant or are nursing or who plan to become pregnant while in the trial * Patients for whom empagliflozin is contraindicated according local label of Jardiance®